Follow Us:

Ed Silverman

Will Federal Healthcare Reform Help Put New Jersey Drugmakers 'In the Money'?
Ed Silverman | November 13, 2013 | Healthcare
More insured people buying more medicine: the math is deceptively simple, but drug companies say the numbers don't necessarily add up
In 'Pharm Country,' Salaries Inch up, As Do Job Openings
Ed Silverman | April 17, 2013 | Healthcare
Guardedly optimistic: the outlook for the biopharma sector in New Jersey and the major metropolitan area.
Retraining Program Helps Former Employees of Big Pharma Get Back to Work
Ed Silverman | March 18, 2013 | Healthcare
New Jersey Department of Labor focuses on folks who lost jobs in latest round of consolidations and relocations
As NJ Sheds Pharma Jobs, Other Major Metro Areas Emerge as New Hubs for Life Sciences
Ed Silverman | February 11, 2013 | Healthcare
Downsizing, consolidation, relocation take toll on New Jersey's pharmaceutical sector
Restocking the Nation's Medicine Chest
Ed Silverman | September 5, 2012 | Healthcare
Allergan agrees to open R&D center in NJ, raising questions about what really attracts pharmaceutical companies to the state.
Angels Sought for NJ’s Emerging Technologies
Ed Silverman | April 9, 2012 | Healthcare
Bankrolling New Jersey Biotechs
Ed Silverman | November 16, 2011 | Healthcare
Realigning a high-tech incentive program so that it only applies to biotechs could give New Jersey more of what it needs: high-quality, high-paying jobs.
Small Town Feels the Effect of Merck Consolidation
Ed Silverman | January 28, 2011 | Healthcare
The loss of some 1,400 jobs in Kenilworth will touch restaurateurs and real estate agents, and is emblematic of changes in the pharmaceutical sector throughout the state.
Cooperation Is the Key for NJ's Universities and Biotechs
Ed Silverman | November 29, 2010 | Healthcare
Academia and industry are just starting to work together in the Garden State. Can each deliver what the other needs to thrive?
Proposed Budget Cuts Could Hurt Cash-Strapped Biotechs
Ed Silverman | June 14, 2010 |
Finding enough cash to conduct their operations is job No. 1 for New Jersey's numerous biotechs.
No Clean Bill of Health for New Jersey's Big Pharma
Ed Silverman | May 10, 2010 |
Cutbacks, mergers, and layoffs; intense competition from lower-cost generics; and fierce rivalry from other regions make for a troubled prognosis for NJ’s big drug makers.
Corporate Supporters
Most Popular Stories